Treatment of Aspergillus fumigatus with Elevated IgG/IgM and Hemoptysis
Diagnostic Confirmation
- The Infectious Diseases Society of America recommends obtaining a CT chest with contrast to identify cavitation, fungal balls, pleural thickening, pericavitary infiltrates, or nodular lesions that characterize chronic cavitary pulmonary aspergillosis (CCPA) 3
- The diagnosis of CCPA requires ≥3 months of chronic pulmonary symptoms or progressive radiographic abnormalities, according to the Infectious Diseases Society of America 1, 3
- Minimal immunocompromise (≤10 mg prednisolone daily or equivalent) and underlying lung disease such as prior TB, COPD, bronchiectasis, or sarcoidosis should be confirmed, as stated by the Infectious Diseases Society of America 3
- Elevated Aspergillus IgG is the most sensitive microbiological test for CCPA diagnosis, with a diagnostic cut-off of 27 mgA/L showing 95.6% sensitivity and 100% specificity, as reported by the Infectious Diseases Society of America 1
First-Line Antifungal Treatment
- The Infectious Diseases Society of America recommends initiating oral azole therapy immediately, with itraconazole as the first choice, and voriconazole as the second choice, both with therapeutic drug monitoring (TDM) 1, 2, 3
- The minimum treatment duration is 6 months, though many patients require long-term or even lifelong therapy for progressive disease, according to the Infectious Diseases Society of America 1, 2
Hemoptysis Management
- The Infectious Diseases Society of America recommends addressing hemoptysis through a stepwise approach, starting with oral tranexamic acid for acute bleeding episodes, followed by bronchial artery embolization if medical management fails, and finally surgical resection for persistent hemoptysis despite bronchial artery embolization 1, 2
- Antifungal therapy itself helps prevent recurrence of hemoptysis, as stated by the Infectious Diseases Society of America 1, 2